Big Pharma Split Corp Class A Cash Flow Quality Index
Big Pharma Split Corp Class A cash flow quality index. Big Pharma Split Corp Class A (PRM) has a Cash Flow Quality Index of -0.55x as of June 2026. Operating cash flow of CA$-1.04 Million is below net income of CA$1.87 Million, suggesting accrual-heavy earnings not yet converted to cash. See how financially flexible is Big Pharma Split Corp Class A to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Big Pharma Split Corp Class A (2018–2025)
Cash flow quality index of Big Pharma Split Corp Class A from 2018 to 2025. Historical Cash Flow Quality Index for Big Pharma Split Corp Class A across 5 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore Big Pharma Split Corp Class A (PRM) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Big Pharma Split Corp Class A Cash Flow Quality Index by Year (2018–2025)
Big Pharma Split Corp Class A cash flow quality index by year from 2018 to 2025. Year-by-year earnings quality comparison for Big Pharma Split Corp Class A. For the full cash flow conversion analysis, see PRM operating cash flow.
| Year | Quality Index | Operating CF (CAD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | -0.24x | CA$-1.06 Million | CA$4.40 Million | ▼ -150.8% |
| 2022 | 0.47x | CA$1.13 Million | CA$2.39 Million | ▲ +122.1% |
| 2021 | -2.14x | CA$-9.00 Million | CA$4.21 Million | ▼ -163.6% |
| 2019 | 3.36x | CA$8.68 Million | CA$2.58 Million | ▲ +457.3% |
| 2018 | 0.60x | CA$1.27 Million | CA$2.10 Million | — |